TCBI:NASDAQTexas Capital Bancshares, Inc. Analysis
Data as of 2026-05-04 - not real-time
$100.85
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Texas Capital Bancshares delivered a strong Q1 2026 earnings beat, posting $1.58 EPS versus the $1.42 consensus and a 63% YoY surge in net income to $69.5 million. Revenue grew 17% year‑over‑year, while operating and profit margins sit at robust 32% and 28.7% respectively, underscoring solid profitability. The stock trades at $100.85, just above the 30‑day support of $96.35 and marginally below the 20‑day SMA of 101.66, indicating a price near a technical floor but still within the bullish trend band defined by the 50‑day (97.30) and 200‑day (91.64) averages. Volume is on an upward trajectory, and the RSI of 52 signals a neutral stance, though the MACD histogram remains negative, hinting at short‑term downside pressure.
Valuation appears attractive: the forward PE of 12.0 is well under the industry average of 17.5, and the price‑to‑book of 1.34 reflects a modest premium to book value. Analysts project a median target of $107, implying roughly 6% upside, while the DCF model suggests a far higher fair value, highlighting potential undervaluation. The dividend yield of 0.79% is modest but payable from a cash pile of $2.9 billion, supporting sustainability. Risks include elevated 30‑day volatility (≈25%), a beta above 1, and sector‑specific credit and regulatory headwinds, yet the balance sheet’s low leverage and strong cash generation mitigate downside concerns.
Valuation appears attractive: the forward PE of 12.0 is well under the industry average of 17.5, and the price‑to‑book of 1.34 reflects a modest premium to book value. Analysts project a median target of $107, implying roughly 6% upside, while the DCF model suggests a far higher fair value, highlighting potential undervaluation. The dividend yield of 0.79% is modest but payable from a cash pile of $2.9 billion, supporting sustainability. Risks include elevated 30‑day volatility (≈25%), a beta above 1, and sector‑specific credit and regulatory headwinds, yet the balance sheet’s low leverage and strong cash generation mitigate downside concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent earnings beat and strong profit margins
- Price hovering near technical support with bearish MACD signal
- Elevated short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward PE below industry average indicating value
- Revenue growth of ~17% and expanding operating cash flow
- Analyst price target suggesting ~6% upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong balance sheet with low leverage and ample cash
- Sustainable dividend supported by cash generation
- Potential sector recovery and long‑term DCF upside
Key Metrics & Analysis
Financial Health
Revenue Growth16.90%
Profit Margin28.67%
P/E Ratio13.6
ROE10.15%
ROA1.10%
P/B Ratio1.3
Op. Cash Flow$447.3M
Industry P/E17.5
Technical Analysis
TrendBullish
RSI52.4
Support$96.35
Resistance$106.82
MA 20$101.66
MA 50$97.30
MA 200$91.64
MACDBearish
VolumeIncreasing
Fear & Greed Index88.63
Valuation
Fair Value$238.24
Target Price$107.38
Upside/Downside6.48%
GradeUndervalued
TypeGrowth
Dividend Yield0.79%
Risk Assessment
Beta1.20
Volatility24.78%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.